Načítá se...
Application of CRISPR/Cas9 Technology to HBV
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...
Uloženo v:
| Vydáno v: | Int J Mol Sci |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4661809/ https://ncbi.nlm.nih.gov/pubmed/26540039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms161125950 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|